Evidence Explorer / MS-N209 / Unsupported cure claims and safety / Appraised November 2, 2026
Hydrazine sulfate has been promoted both as an anticancer treatment and as a way to reverse cancer-associated weight loss. Randomized human trials did not show anticancer benefit, and the cachexia evidence remains inconclusive. It is not an approved cancer treatment.
Evidence at a glance
- Population: a key placebo-controlled trial randomized 243 people with newly diagnosed, unresectable non-small-cell lung cancer receiving cisplatin and etoposide.
- Comparator: hydrazine sulfate versus placebo added to the same chemotherapy.
- Results: response rates were similar; time-to-progression and survival trends favored placebo, and quality of life did not improve.
- Cachexia question: NCI’s review describes mixed, methodologically limited findings rather than a reliable benefit.
- Evidence label: negative randomized cancer-control evidence; inconclusive symptom-support evidence; meaningful safety concern.
What was studied
The multicenter trial enrolled 243 participants. Hydrazine sulfate did not improve tumor response or quality of life. The published abstract reported trends toward worse time to progression and survival in the hydrazine group, although the record does not provide all absolute estimates or confidence intervals.
NCI’s PDQ review also considered other randomized studies and found no established anticancer activity. Reports concerning appetite or weight loss were inconsistent and do not justify treating a laboratory or metabolic hypothesis as a patient benefit.
What this evidence cannot establish
Hydrazine sulfate has not been shown to shrink tumors, delay progression, extend survival or reliably reverse cancer cachexia. A change in appetite, weight or a metabolic marker would not by itself demonstrate cancer control.
The checked sources do not provide a formulation standard, a safe self-treatment dose, complete adherence data, or a current interaction profile. Funding and conflicts for the randomized trial were not verified from the accessible abstract.
Practical safety context
Hydrazine compounds are toxic and hydrazine sulfate has been considered a potential carcinogenic hazard. Neurologic and gastrointestinal toxicity have been reported; the product should not be combined with cancer therapy outside a properly monitored clinical study.
Unintentional weight loss during cancer treatment needs assessment for tumor burden, treatment toxicity, swallowing problems, depression, malabsorption and other treatable causes. Substituting hydrazine sulfate can delay effective nutrition and symptom care.
Questions for the care team
- What is driving the weight loss, and which reversible causes have been checked?
- Which evidence-based nutrition, medication or symptom strategies fit the goal?
- Could this product interact with chemotherapy, supportive medicines or neurologic conditions?
Sources
Source note: The NCI evidence summary and PubMed abstract were checked. The full trial text was not accessible in this appraisal, so unsupported numerical details were omitted. No correction, retraction or expression of concern was identified in the PubMed record on November 2, 2026.
This record is educational, not a personal treatment recommendation. Hydrazine sulfate should not replace oncology care or evidence-based management of cancer-associated weight loss.
